Cargando…

External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors

INTRODUCTION: Pulmonary toxicity is dose-limiting in stereotactic body radiation therapy (SBRT) for tumors that abut the proximal bronchial tree (PBT), esophagus, or other mediastinal structures. In this work we explored published models of pulmonary toxicity following SBRT for such ultracentral tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ishita, Wu, Abraham J., Jackson, Andrew, Patel, Purvi, Sun, Lian, Ng, Angela, Iyer, Aditi, Apte, Aditya, Rimner, Andreas, Gomez, Daniel, Deasy, Joseph O., Thor, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646645/
https://www.ncbi.nlm.nih.gov/pubmed/36388248
http://dx.doi.org/10.1016/j.ctro.2022.10.012
_version_ 1784827213298794496
author Chen, Ishita
Wu, Abraham J.
Jackson, Andrew
Patel, Purvi
Sun, Lian
Ng, Angela
Iyer, Aditi
Apte, Aditya
Rimner, Andreas
Gomez, Daniel
Deasy, Joseph O.
Thor, Maria
author_facet Chen, Ishita
Wu, Abraham J.
Jackson, Andrew
Patel, Purvi
Sun, Lian
Ng, Angela
Iyer, Aditi
Apte, Aditya
Rimner, Andreas
Gomez, Daniel
Deasy, Joseph O.
Thor, Maria
author_sort Chen, Ishita
collection PubMed
description INTRODUCTION: Pulmonary toxicity is dose-limiting in stereotactic body radiation therapy (SBRT) for tumors that abut the proximal bronchial tree (PBT), esophagus, or other mediastinal structures. In this work we explored published models of pulmonary toxicity following SBRT for such ultracentral tumors in an independent cohort of patients. METHODS: The PubMed database was searched for pulmonary toxicity models. Identified models were tested in a cohort of patients with ultracentral lung tumors treated between 2008 and 2017 at one large center (N = 88). This cohort included 60 % primary and 40 % metastatic tumors treated to 45 Gy in 5 fractions (fx), 50 Gy in 5 fx, 60 Gy in 8 fx, or 60 Gy in 15 fx prescribed as 100 % dose to PTV. RESULTS: Seven published NTCP models from two studies were identified. The NTCP models utilized PBT max point dose (Dmax), D0.2 cm(3), V65, V100, and V130. Within the independent cohort, the ≥ grade 3 toxicity and grade 5 toxicity rates were 18 % and 7–10 %, respectively, and the Dmax models best described pulmonary toxicity. The Dmax to 0.1 cm(3) model was better calibrated and had increased steepness compared to the Dmax model. A re-planning study minimizing PBT 0.1 cm(3) to below 122 Gy in EQD2(3) (for a 10 % ≥grade 3 pulmonary toxicity) was demonstrated to be completely feasible in 4/6 patients, and dose to PBT 0.1 cm(3) was considerably lowered in all six patients. CONCLUSIONS: Pulmonary toxicity models were identified from two studies and explored within an independent ultracentral lung tumor cohort. A modified Dmax to 0.1 cm(3) PBT model displayed the best performance. This model could be utilized as a starting point for rationally constructed airways constraints in ultracentral patients treated with SBRT or hypofractionation.
format Online
Article
Text
id pubmed-9646645
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96466452022-11-15 External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors Chen, Ishita Wu, Abraham J. Jackson, Andrew Patel, Purvi Sun, Lian Ng, Angela Iyer, Aditi Apte, Aditya Rimner, Andreas Gomez, Daniel Deasy, Joseph O. Thor, Maria Clin Transl Radiat Oncol Article INTRODUCTION: Pulmonary toxicity is dose-limiting in stereotactic body radiation therapy (SBRT) for tumors that abut the proximal bronchial tree (PBT), esophagus, or other mediastinal structures. In this work we explored published models of pulmonary toxicity following SBRT for such ultracentral tumors in an independent cohort of patients. METHODS: The PubMed database was searched for pulmonary toxicity models. Identified models were tested in a cohort of patients with ultracentral lung tumors treated between 2008 and 2017 at one large center (N = 88). This cohort included 60 % primary and 40 % metastatic tumors treated to 45 Gy in 5 fractions (fx), 50 Gy in 5 fx, 60 Gy in 8 fx, or 60 Gy in 15 fx prescribed as 100 % dose to PTV. RESULTS: Seven published NTCP models from two studies were identified. The NTCP models utilized PBT max point dose (Dmax), D0.2 cm(3), V65, V100, and V130. Within the independent cohort, the ≥ grade 3 toxicity and grade 5 toxicity rates were 18 % and 7–10 %, respectively, and the Dmax models best described pulmonary toxicity. The Dmax to 0.1 cm(3) model was better calibrated and had increased steepness compared to the Dmax model. A re-planning study minimizing PBT 0.1 cm(3) to below 122 Gy in EQD2(3) (for a 10 % ≥grade 3 pulmonary toxicity) was demonstrated to be completely feasible in 4/6 patients, and dose to PBT 0.1 cm(3) was considerably lowered in all six patients. CONCLUSIONS: Pulmonary toxicity models were identified from two studies and explored within an independent ultracentral lung tumor cohort. A modified Dmax to 0.1 cm(3) PBT model displayed the best performance. This model could be utilized as a starting point for rationally constructed airways constraints in ultracentral patients treated with SBRT or hypofractionation. Elsevier 2022-11-04 /pmc/articles/PMC9646645/ /pubmed/36388248 http://dx.doi.org/10.1016/j.ctro.2022.10.012 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Chen, Ishita
Wu, Abraham J.
Jackson, Andrew
Patel, Purvi
Sun, Lian
Ng, Angela
Iyer, Aditi
Apte, Aditya
Rimner, Andreas
Gomez, Daniel
Deasy, Joseph O.
Thor, Maria
External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
title External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
title_full External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
title_fullStr External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
title_full_unstemmed External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
title_short External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
title_sort external validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646645/
https://www.ncbi.nlm.nih.gov/pubmed/36388248
http://dx.doi.org/10.1016/j.ctro.2022.10.012
work_keys_str_mv AT chenishita externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT wuabrahamj externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT jacksonandrew externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT patelpurvi externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT sunlian externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT ngangela externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT iyeraditi externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT apteaditya externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT rimnerandreas externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT gomezdaniel externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT deasyjosepho externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors
AT thormaria externalvalidationofpulmonaryradiotherapytoxicitymodelsforultracentrallungtumors